Check Cap (NASDAQ: CHEK) and Hologic (NASDAQ:HOLX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
This table compares Check Cap and Hologic’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
Check Cap has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, Hologic has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
Institutional & Insider Ownership
97.5% of Hologic shares are held by institutional investors. 0.8% of Hologic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Check Cap and Hologic’s revenue, earnings per share and valuation.
||Earnings Per Share
Hologic has higher revenue and earnings than Check Cap. Check Cap is trading at a lower price-to-earnings ratio than Hologic, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and target prices for Check Cap and Hologic, as provided by MarketBeat.com.
||Strong Buy Ratings
Check Cap presently has a consensus price target of $5.50, suggesting a potential upside of 30.02%. Hologic has a consensus price target of $47.54, suggesting a potential upside of 22.87%. Given Check Cap’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Check Cap is more favorable than Hologic.
Hologic beats Check Cap on 11 of the 13 factors compared between the two stocks.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.